<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231209060299N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-05-29</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of orthoses on gait in individuals with multiple sclerosis and foot drop.</public_title>
      <acronym></acronym>
      <scientific_title>The comparison of the immediate effects of UD-Flex and PLS orthoses on spatiotemporal gait parameters in individuals with Multiple Sclerosis and Drop foot: A randomized crossover clinical study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-05-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>12</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/89999</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Supportive, Randomization description: Randomization method in this study was simple randomization. Due to the cross-over design and the random order of all three conditions (barefoot, PLS orthosis, and UD-Flex orthosis), simple randomization was used to determine the sequence of testing. Given the limited sample size (12 participants) and the absence of different subgroups, block or stratified randomization methods were not required, and there were no randomization layers. The unit of randomization was the individual, and each participant independently received their own sequence of interventions. Each of the 6 possible sequences (3!) was written on cards and placed inside opaque, non-visible envelopes. The envelopes were numbered and sealed by an individual independent of the researcher. The random sequence was generated using a random number table by a person independent of the researcher before the start of the study. Considering the three conditions (barefoot, PLS orthosis, UD-Flex orthosis) and the completely random order of their execution, all 6 possible permutations (3!) were considered equally likely. For each participant, a two-digit random number was selected from the random number table, and based on the remainder of division by 6 (0 to 5), one of the 6 sequences was randomly determined. Allocation concealment was performed using opaque, sealed, sequentially numbered envelopes. The researcher was unaware of the sequence of conditions until the time of testing and opening the envelope corresponding to each patient. After recording the patient's characteristics and confirming the inclusion criteria, the corresponding envelope was opened in numerical order, and the test sequence was executed according to the envelope's contents. This method prevented bias in the allocation of intervention order. An important point is that the barefoot condition was considered the control condition (without intervention), and the randomization of its order did not change its control nature. A 10-minute rest period was provided between different tests to eliminate fatigue and carryover effects, Blinding description: Since all participants are assessed under all three conditions (and are not divided into intervention and control groups), it is not possible to blind the participants or the assessor. To maintain single blinding, the data analyst will be unaware of how the intervention (type of orthosis) was allocated in each test session. For this purpose, all raw data collected by the motion analysis system will be coded before being delivered to the analyst, so that they will not be able to identify the type of intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Foot drop in multiple sclerosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group 1: PLS orthosis; a type of ankle-foot orthosis placed on the posterior side of the calf and ankle, custom-made for each patient at the Orthotics and Prosthetics Clinic of Kashani Hospital, Isfahan, Iran. This orthosis is made of thermoplastic polypropylene material. It also has a non-slip rubber footplate and is worn without shoes. After putting on the orthosis, the participant walks along a 7-meter path, and their movements are recorded by a motion analysis system. It is worth noting that the effect of the orthosis is immediate and short-term, and its effect disappears as soon as the orthosis is removed. Nevertheless, a 10-minute rest period is provided between different tests to eliminate fatigue and carryover effects. Intervention 2: Intervention Group 2: UD-Flex orthosis; a prefabricated orthosis manufactured by ADVANFIT INC., Japan, which is placed on the anterior side of the ankle, allowing the heel to freely contact the ground during walking. After precise measurement of each patient's foot dimensions (foot length, foot width, and calf circumference), the appropriate orthosis size is selected from the available standard sizes based on the manufacturer's sizing chart. The individual wears this orthosis without shoes. After donning the orthosis, the participant walks along a 7-meter path, and their movements are recorded by a motion analysis system. It is worth noting that the effect of the orthosis is immediate and short-term, and its effect disappears as soon as the orthosis is removed. Nevertheless, a 10-minute rest period is provided between different tests to eliminate fatigue and carryover effects. Intervention 3: Control Group: Barefoot (without orthosis); the barefoot condition is considered the control condition (without intervention), in which the participant walks barefoot along a 7-meter path, and their movements are recorded by a motion analysis system. A 10-minute rest period is provided between different tests to eliminate fatigue and carryover effects.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Study data (excluding personal information) will be shared with other researchers.

When:
The data will be shared after the publication of the results or a summary of the data.

To whom:
The data will be shared solely for academic purposes.

Conditions:
The data will be shared for teaching and research purposes of the applicants.

Where to obtain:
Individuals can request the information from the designated responsible person.

How to obtain:
Requests must be sent via email (asiyaeimehr@rehab.mui.ac.ir).

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr.Hossein Asiyaeimehr</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Rehabilitation, Isfahan University of Medical Sciences, Hezar Jarib Street, Isfahan, Iran</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3792 5081</telephone>
        <email>asiyaeimehr@rehab.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Hossein Asiyaeimehr</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Rehabilitation, Isfahan University of Medical Sciences, Hezar Jarib Street, Isfahan, Iran</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3792 5081</telephone>
        <email>asiyaeimehr@rehab.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People with relapsing-remitting multiple sclerosis who are in the remission phase.
individuals with drop foot.
Maximum spasticity in the ankle plantar flexor muscles should be grade 2 according to the Modified Ashworth Scale (MAS).
The patient's disability score should be between 4 and 6.
Patients aged 20–50 years.
The individual should be able to walk 20 meters without assistance from others or with the use of a walking aid.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Individuals who have had a relapse (exacerbation) of the disease within the past 3 months, as confirmed by a physician.
Individuals with impaired consciousness who cannot provide informed consent.
Musculoskeletal disorders that impair the individual's walking.
Individuals who have severe cardiac or respiratory problems that prevent the patient's participation and the performance of the tests.
History of fractures or surgeries of the lower limbs, ankle sprain, osteoarthritis, and pain that severely limits walking.
Individuals with psychiatric disorders.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G35</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Multiple sclerosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group 1: PLS orthosis; a type of ankle-foot orthosis placed on the posterior side of the calf and ankle, custom-made for each patient at the Orthotics and Prosthetics Clinic of Kashani Hospital, Isfahan, Iran. This orthosis is made of thermoplastic polypropylene material. It also has a non-slip rubber footplate and is worn without shoes. After putting on the orthosis, the participant walks along a 7-meter path, and their movements are recorded by a motion analysis system. It is worth noting that the effect of the orthosis is immediate and short-term, and its effect disappears as soon as the orthosis is removed. Nevertheless, a 10-minute rest period is provided between different tests to eliminate fatigue and carryover effects.</i_keyword>
      <i_keyword>Intervention Group 2: UD-Flex orthosis; a prefabricated orthosis manufactured by ADVANFIT INC., Japan, which is placed on the anterior side of the ankle, allowing the heel to freely contact the ground during walking. After precise measurement of each patient's foot dimensions (foot length, foot width, and calf circumference), the appropriate orthosis size is selected from the available standard sizes based on the manufacturer's sizing chart. The individual wears this orthosis without shoes. After donning the orthosis, the participant walks along a 7-meter path, and their movements are recorded by a motion analysis system. It is worth noting that the effect of the orthosis is immediate and short-term, and its effect disappears as soon as the orthosis is removed. Nevertheless, a 10-minute rest period is provided between different tests to eliminate fatigue and carryover effects.</i_keyword>
      <i_keyword>Control Group: Barefoot (without orthosis); the barefoot condition is considered the control condition (without intervention), in which the participant walks barefoot along a 7-meter path, and their movements are recorded by a motion analysis system. A 10-minute rest period is provided between different tests to eliminate fatigue and carryover effects.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cadence. Timepoint: Measurements are performed randomly under three conditions: barefoot, immediately after wearing the PLS orthosis following a 5-minute accommodation period, and immediately after wearing the UD-Flex orthosis following a 5-minute accommodation period. All measurements are conducted in a single session to assess the immediate effect, and there is no follow-up period (daily or weekly). The assessment frequency is only once per condition. Method of measurement: Qualisys motion capture system.</prim_outcome>
      <prim_outcome>Walking speed. Timepoint: Measurements are performed randomly under three conditions: barefoot, immediately after wearing the PLS orthosis following a 5-minute accommodation period, and immediately after wearing the UD-Flex orthosis following a 5-minute accommodation period. All measurements are conducted in a single session to assess the immediate effect, and there is no follow-up period (daily or weekly). The assessment frequency is only once per condition. Method of measurement: Qualisys motion capture system.</prim_outcome>
      <prim_outcome>Step length. Timepoint: Measurements are performed randomly under three conditions: barefoot, immediately after wearing the PLS orthosis following a 5-minute accommodation period, and immediately after wearing the UD-Flex orthosis following a 5-minute accommodation period. All measurements are conducted in a single session to assess the immediate effect, and there is no follow-up period (daily or weekly). The assessment frequency is only once per condition. Method of measurement: Qualisys motion capture system.</prim_outcome>
      <prim_outcome>Step width. Timepoint: Measurements are performed randomly under three conditions: barefoot, immediately after wearing the PLS orthosis following a 5-minute accommodation period, and immediately after wearing the UD-Flex orthosis following a 5-minute accommodation period. All measurements are conducted in a single session to assess the immediate effect, and there is no follow-up period (daily or weekly). The assessment frequency is only once per condition. Method of measurement: Qualisys motion capture system.</prim_outcome>
      <prim_outcome>Double support time. Timepoint: Measurements are performed randomly under three conditions: barefoot, immediately after wearing the PLS orthosis following a 5-minute accommodation period, and immediately after wearing the UD-Flex orthosis following a 5-minute accommodation period. All measurements are conducted in a single session to assess the immediate effect, and there is no follow-up period (daily or weekly). The assessment frequency is only once per condition. Method of measurement: Qualisys motion capture system.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-04-18</approval_date>
        <contact_name>Ethics Committee of Nursing, Rehabilitation &amp; Management schools- Isfahan</contact_name>
        <contact_address>School of Rehabilitation, Isfahan University of Medical Sciences, Hezar Jarib Street, Isfahan Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
